Insmed Incorporated is dedicated to developing innovative therapies aimed at addressing serious diseases with significant unmet patient needs. The company employs a diverse range of technologies and scientific approaches, including gene therapy, protein engineering, and computational biology, to advance its research and development pipeline. Insmed's research teams, located across multiple laboratories in the U.S. and the UK, collaborate seamlessly to drive innovation and optimize drug formulation and delivery. Their focus on early-stage research allows them to explore uncharted areas of medicine, leveraging advanced methodologies such as artificial intelligence and machine learning to identify and develop next-generation therapeutic candidates.

The company’s product pipeline includes therapies for various conditions, such as nontuberculous mycobacterial lung disease and chronic inflammatory disorders. Insmed is particularly focused on gene therapy, utilizing its proprietary Deimmunized by Design® platform to enhance the efficacy and safety of therapeutic proteins and gene therapies. This platform aims to reduce immunogenicity while maintaining therapeutic function, thereby addressing challenges associated with repeat dosing in gene therapy. Insmed's commitment to innovation is further exemplified by its strategic partnerships and collaborations, which enhance its ability to deliver transformative medicines to patients facing rare and serious diseases.

United States

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients in the United States. It also develops INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug for the treatment of rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Cardiovascular Diseases

Central Nervous System (CNS)

Eye Diseases

Inflammatory disorders

Lung Diseases

Rare diseases

Insmed Incorporated

Mycobacterium avium complex lung disease

Nontuberculous mycobacterial lung disease

Amikacin is a polycationic, semisynthetic, bactericidal aminoglycoside. Amikacin enters the bacterial cell by binding to negatively charged components of the bacterial cell wall disrupting the overall architecture of the cell wall. The primary mechanism of action is the disruption and inhibition of protein synthesis in the target bacteria by binding to the 30S ribosomal subunit.
<a href="https://www.arikayce.com/pdf/full-prescribing-information.pdf?v=2.15.3">Source</a>

ARIKAYCE (Amikacin Liposome Inhalation Suspension)

Non-Cystic Fibrosis Bronchiectasis

Brensocatib is a small molecule, oral, reversible inhibitor of &nbsp;dipeptidyl peptidase 1 (DPP1) being developed by Insmed for the &nbsp;treatment of patients with bronchiectasis and other neutrophil-mediated &nbsp;diseases. DPP1 is an enzyme responsible for activating neutrophil serine &nbsp;proteases (NSPs), such as neutrophil elastase, in neutrophils when they &nbsp;are formed in the bone marrow. Neutrophils are the most common type of &nbsp;white blood cell and play an essential role in pathogen destruction and &nbsp;inflammatory mediation. In chronic inflammatory lung diseases, &nbsp;neutrophils accumulate in the airways and result in excessive active &nbsp;NSPs that cause lung destruction and inflammation. Brensocatib may &nbsp;decrease the damaging effects of inflammatory diseases such as &nbsp;bronchiectasis by inhibiting DPP1 and its activation of NSPs.
<a href="https://investor.insmed.com/2020-12-02-Insmed-Announces-Initiation-of-Phase-3-ASPEN-Study-of-Brensocatib-in-Patients-with-Bronchiectasis">Source</a>

Brensocatib

Interstitial lung disease

Pulmonary hypertension

TPIP (Treprostinil Palmitil Inhalation Powder)

Cystic fibrosis

Brensocatib is a small molecule, oral, reversible inhibitor of &nbsp;dipeptidyl peptidase 1 (DPP1) being developed by Insmed for the &nbsp;treatment of patients with non-cystic fibrosis bronchiectasis (NCFBE) &nbsp;and other neutrophil-mediated diseases. DPP1 is an enzyme responsible &nbsp;for activating neutrophil serine proteases (NSPs), such as neutrophil &nbsp;elastase, in neutrophils when they are formed in the bone marrow. &nbsp;Neutrophils are the most common type of white blood cell and play an &nbsp;essential role in pathogen destruction and inflammatory mediation. In &nbsp;chronic inflammatory lung diseases, neutrophils accumulate in the &nbsp;airways and result in excessive active NSPs that cause lung destruction &nbsp;and inflammation. Brensocatib may decrease the damaging effects of &nbsp;inflammatory diseases such as bronchiectasis by inhibiting DPP1 and its &nbsp;activation of NSPs.
<a href="https://investor.insmed.com/2020-10-29-Insmed-Reports-Third-Quarter-2020-Financial-Results-and-Provides-Business-Update">Source</a>

Insmed Incorporated

Company Details